Literature DB >> 8980988

Pneumonitis during interferon and/or herbal drug therapy in patients with chronic active hepatitis.

T Ishizaki1, F Sasaki, S Ameshima, K Shiozaki, H Takahashi, Y Abe, S Ito, M Kuriyama, T Nakai, M Kitagawa.   

Abstract

We report four cases of acute pneumonitis due either to interferon, or a herbal drug, "Sho-saiko-to", or both in combination, in patients with chronic active hepatitis, focusing on its pathogenesis and response to prednisolone therapy. These cases shared common clinical features: fever, dry cough, dyspnoea, hypoxaemia, diffuse infiltrates both on chest radiography and chest computed tomography, restrictive pulmonary functional impairment, and alveolitis on examination of transbronchial lung biopsy, all of which suggest acute interstitial pneumonia. Furthermore, lymphocytosis was observed in association with the dominant CD8+ T-cell subset in bronchoalveolar lavage fluid. A lymphocyte stimulation test using peripheral blood was positive to interferon in one case and to Sho-saiko-to in another. All patients responded to oral prednisolone therapy. Peripheral soluble interleukin-2 receptor levels decreased in parallel with improvement in the clinical course. All patients were free of symptoms with a follow-up of 1-3 yrs. We conclude that interferon- and/or Sho-saiko-to-induced acute pneumonitis may be due to allergic-immunological mechanisms rather than toxicity, and that peripheral levels of soluble interleukin-2 receptor appear to be good markers of disease activity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8980988     DOI: 10.1183/09031936.96.09122691

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  26 in total

Review 1.  Chinese medicinal herbs for chronic hepatitis B.

Authors:  J P Liu; H McIntosh; H Lin
Journal:  Cochrane Database Syst Rev       Date:  2001

Review 2.  Chinese herbal medicines for hypercholesterolemia.

Authors:  Zhao Lan Liu; Jian Ping Liu; Anthony Lin Zhang; Qiong Wu; Yao Ruan; George Lewith; Denise Visconte
Journal:  Cochrane Database Syst Rev       Date:  2011-07-06

3.  Interstitial Pneumonitis Related to Pegylated Interferon Alfa-2a Treatment in a Patient with Chronic Hepatitis C.

Authors:  Erhan Alkan; Mete Akin; Haydar Adanir; Yasar Tuna
Journal:  Euroasian J Hepatogastroenterol       Date:  2016-07-09

4.  Perceptions and attitudes of Japanese gynecologic cancer patients to Kampo (Japanese herbal) medicines.

Authors:  Takashi Takeda; Takuhiro Yamaguchi; Nobuo Yaegashi
Journal:  Int J Clin Oncol       Date:  2011-06-25       Impact factor: 3.402

Review 5.  Herbal medicines for viral myocarditis.

Authors:  Zhao Lan Liu; Zhi Jun Liu; Jian Ping Liu; Min Yang; Joey Kwong
Journal:  Cochrane Database Syst Rev       Date:  2010-07-07

Review 6.  Diagnosis and management of interstitial pneumonitis associated with interferon therapy for chronic hepatitis C.

Authors:  Fan-Pu Ji; Zheng-Xiao Li; Hong Deng; Hong-An Xue; Yuan Liu; Min Li
Journal:  World J Gastroenterol       Date:  2010-09-21       Impact factor: 5.742

Review 7.  Panax ginseng: a systematic review of adverse effects and drug interactions.

Authors:  Joanna Thompson Coon; Edzard Ernst
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

8.  Ursodeoxycholic acid exacerbates peginterferon-induced interstitial pneumonia in a patient with hepatitis C.

Authors:  Rena Kaneko; Masazumi Ogawa; Tomoyuki Iwata; Yasuyoshi An; Motoki Nakagawa; Satoshi Kusayanagi; Satoshi Kamisago; Tomoyuki Umeda; Yuzuru Sato
Journal:  Clin J Gastroenterol       Date:  2009-05-26

Review 9.  Herbal medicines for viral myocarditis.

Authors:  J P Liu; M Yang; X M Du
Journal:  Cochrane Database Syst Rev       Date:  2004

Review 10.  Pneumonitis as a consequence of (peg)interferon-ribavirin combination therapy for hepatitis C: a review of the literature.

Authors:  Serena Slavenburg; Yvonne F Heijdra; Joost P H Drenth
Journal:  Dig Dis Sci       Date:  2009-04-28       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.